Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Branding Colors Css

HCP's Staquis
  • Home
  • Atopic Dermatitis
  • Identifying patients
  • About Staquis
    • About Staquis
    • Study design
    • Efficacy data
    • Safety profile
  • Information
    • Instructions for use (PI)

  1. Home
  2. Staquis

 

 

 

Atopic Dermatitis

AD is a common chronic inflammatory skin condition driven by skin barrier disruption and immune system...

Assessing AD

The Investigator's Static Global Assessment (ISGA) scale is used to evaluate the severity of AD.

Efficacy data

Percentage of patients with success in ISGA score.

Instructions for use

Staquis® is for topical use only and not for ophthalmic, oral or intravaginal use.

Thank you for being interested in receiving more information!
You will soon be leaving Pfizer.co.il.
Pfizer bears no responsibility for the content of external websites or in connection with the information provided by them. Pfizer does not accept any liability in connection to any information these websites provide.

Continue Cancel

September 2023

PP-STA-ISR-0161

The information provided on this website is intended for health care professionals in Israel only. 

  • Privacy policy
  • Cookie policy
  • Terms of use for professional staff
  • Accessibility statement

Sponsored by Pfizer.
Pfizer Pharmaceuticals Israel Ltd. Is registered in Israel under private company no. 512092115. Pfizer PFE Pharmaceuticals Israel Ltd. Is registered in Israel under private company no. 515105385.
All rights reserved ©. Our address: 9 Shenkar Street, Herzliya.
For questions about the company, its commercial operations in the healthcare field or to receive information about the company’s medications, please contact Pfizer Pharmaceuticals Israel Ltd.
At Tel 972-9-970-0500 or by e-mail [email protected]

To report side effects: [email protected] | To report quality complaints: [email protected] | For inquiries regarding medical information: [email protected]
For Ministry of Health side effect reporting: www.sideeffects.health.gov.il

Tel 972-9-970-0500 | Fax 972-9-970-0501 | Website pfizer.co.il

PP-UNP-ISR-0036